FindTrial
Sign In

Comparison of plasma concentration and efficacy of continuous administration and infusion of piperacillin tazobactam in sepsis patients

Comparison of plasma concentration and efficacy of continuous administration and infusion of piperacillin tazobactam in sepsis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17013364
Enrollment
Unknown
Registered
2017-11-13
Start date
2017-12-01
Completion date
Unknown
Last updated
2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

A:Piperacillin tazobactam intravenous injection to maintain
B:Piperacillin tazobactam intravenous injection intermittently

Sponsors

Shanghai 6th People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. The patients met the criteria for the 3.0 diagnosis of sepsis; qSOFA = 2; 2. The patient's BMI 18.5-24.9; 3. The patient's condition needs to be treated with piperacillin tazobactam.;Inclusion criteria: 1. The patients met the criteria for the 3.0 diagnosis of sepsis; qSOFA = 2; 2. The patient's BMI 18.5-24.9; 3. The patient's condition needs to be treated with piperacillin tazobactam.

Exclusion criteria

Exclusion criteria: 1. Penicillin allergy patients; 2. Patients who need CRRT.;Exclusion criteria: 1. Penicillin allergy patients; 2. Patients who need CRRT.

Design outcomes

Primary

MeasureTime frame
serum drug concentration of piperacillin tazobactam;blood routine test;PCT;;serum drug concentration of piperacillin tazobactam;blood routine test;PCT;—

Countries

China

Contacts

Public ContactHuang Weifeng;Huang Weifeng ;

Shanghai 6th People's Hospital;Shanghai 6th People's Hospital

364512121@qq.com;364512121@qq.com+86 18930173670;+86 18930173670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026